$Eli Lilly(LLY)$ Now it's time

Now it's time for some facts.

Lly Earnings are forecasted to increase for the next 2 quarters going forward.

Based on analyst ratings, Eli Lilly’s 12 month average price target is $943.00 Eli Lilly has a 17% upside potential based on the analysts' average target price and the current price of $804.

Now I believe this analyst rating may have occurred before the price drop. Based on the original 7.3% upside, the stock was probably around $880 a share when they were calculating the upside potential.

On the low side I have seen other analysts who say the average Target prices $858 a share. Still with a 7% upside potential.

Regardless, that should not change the outlook consensus which is based on sales projections. so in theory, the upside is still there.

Eli Lilly & Co has a consensus rating of Strong Buy which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.

There is my "pump" for the day.

My opinion? The earning season continues for this stock.

LLY Beats vs. NVO Misses:Which Weight Loss Drug Do You Favor?

Eli Lilly expects fiscal year revenue to be between $45.4 billion and $46.6 billion, up from the previous forecast of $42.4 billion to $43.6 billion. Eli Lilly's stock surged 10% in pre-market trading. Novo Nordisk (NVO) stock tumbled Wednesday after the Danish drugmaker reported a rare sales miss. ------------ Which weight loss drug company is a better buy?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":335806455943208,"tweetId":"335806455943208","gmtCreate":1723019753036,"gmtModify":1723021951829,"author":{"id":9000000000000360,"idStr":"9000000000000360","authorId":9000000000000360,"authorIdStr":"9000000000000360","name":"snoozi","avatar":"https://static.tigerbbs.com/baf2072a17d25a1d36d3d9998b259d99","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":122,"starInvestorFlag":false},"themes":[{"themeId":"3ba18faeb8364f42b810a81bee429b4d","categoryId":"7a15628ce2174325bddc6229505e0d70","name":"LLY Beats vs. NVO Misses:Which Weight Loss Drug Do You Favor?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":3ba18faeb8364f42b810a81bee429b4d}&rnconfig={\"headerBarHidden\": true}","description":"Eli Lilly expects fiscal year revenue to be between $45.4 billion and $46.6 billion, up from the previous forecast of $42.4 billion to $43.6 billion. Eli Lilly's stock surged 10% in pre-market trading.\nNovo Nordisk (NVO) stock tumbled Wednesday after the Danish drugmaker reported a rare sales miss.\n------------\nWhich weight loss drug company is a better buy?","image":"https://community-static.tradeup.com/news/96ede51e656d3728375f75b1fee3f8e4"}],"images":[{"img":"https://community-static.tradeup.com/news/9be017a86b7c7badebc64299f01ad570","width":"545","height":"275"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/9be017a86b7c7badebc64299f01ad570","width":"545","height":"275"}],"html":"<html><head></head><body> <a data-mention-id=\"LLY\" class=\"teditor-mention\" data-mention-name=\"Eli Lilly\" href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> Now it's time for some facts.Lly Earnings are forecasted to increase for the next 2 quarters going forward.Based on analyst ratings, Eli Lilly’s 12 month average price target is $943.00 Eli Lilly has a 17% upside potential based on the analysts' average target price and the current price of $804. Now I believe this analyst rating may have occurred before the price drop. Based on the original 7.3% upside, the stock was probably around $880 a share when they were calculating the upside potential. On the low side I have seen other analysts who say the average Target prices $858 a share. Still with a 7% upside potential.Regardless, that should not change the outlook consensus which is based on sales projections. so in theory, the upside is still there. Eli Lilly &amp; Co has a consensus rating of Strong Buy which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.There is my \"pump\" for the day.My opinion? The earning season continues for this stock.<img src=\"https://community-static.tradeup.com/news/9be017a86b7c7badebc64299f01ad570\" tg-width=\"545\" tg-height=\"275\"></body></html>","htmlText":"<html><head></head><body> <a data-mention-id=\"LLY\" class=\"teditor-mention\" data-mention-name=\"Eli Lilly\" href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> Now it's time for some facts.Lly Earnings are forecasted to increase for the next 2 quarters going forward.Based on analyst ratings, Eli Lilly’s 12 month average price target is $943.00 Eli Lilly has a 17% upside potential based on the analysts' average target price and the current price of $804. Now I believe this analyst rating may have occurred before the price drop. Based on the original 7.3% upside, the stock was probably around $880 a share when they were calculating the upside potential. On the low side I have seen other analysts who say the average Target prices $858 a share. Still with a 7% upside potential.Regardless, that should not change the outlook consensus which is based on sales projections. so in theory, the upside is still there. Eli Lilly &amp; Co has a consensus rating of Strong Buy which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.There is my \"pump\" for the day.My opinion? The earning season continues for this stock.<img src=\"https://community-static.tradeup.com/news/9be017a86b7c7badebc64299f01ad570\" tg-width=\"545\" tg-height=\"275\"></body></html>","text":"$Eli Lilly(LLY)$ Now it's time for some facts. Lly Earnings are forecasted to increase for the next 2 quarters going forward. Based on analyst ratings, Eli Lilly’s 12 month average price target is $943.00 Eli Lilly has a 17% upside potential based on the analysts' average target price and the current price of $804. Now I believe this analyst rating may have occurred before the price drop. Based on the original 7.3% upside, the stock was probably around $880 a share when they were calculating the upside potential. On the low side I have seen other analysts who say the average Target prices $858 a share. Still with a 7% upside potential. Regardless, that should not change the outlook consensus which is based on sales projections. so in theory, the upside is still there. Eli Lilly & Co has a consensus rating of Strong Buy which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings. There is my \"pump\" for the day. My opinion? The earning season continues for this stock.","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/335806455943208","repostId":0,"isVote":1,"tweetType":1,"viewCount":310,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["LLY"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":814,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/335806455943208"}